NEWS & EVENTS

Catalent today welcomed the announcement by Biohaven Pharmaceutical, that the U.S. Food and Drug Administration has approved its NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults.

Catalent welcomes the announcement by Blueprint Medicines Corporation that the FDA has approved AYVAKIT™ for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.

Perrigo and Catalent today announced that the FDA has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA

Catalent today announced that Senior Vice President & Chief Financial Officer, Wetteny Joseph, has been inducted as a member of the Executive Leadership Council (ELC).

Catalent today announced it will host a one day workshop titled, “Achieving Integrated Biologics Development: Challenges and How to Tackle Them”.

Catalent today announced the appointment of Jim Walter as Vice President of Operations for its Oral and Specialty Delivery business.

Catalent today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors.

Catalent, Inc. today announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.

Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2020 in the United States.